Medicine: Lilly schizophrenia drug shows promise in trial

So Lilly has some sort of glutamatergic antipsychotic in the works?

Eli Lilly and Co. on Thursday said one of its experimental drugs was comparably effective in a mid-stage trial as the company's widely used Zyprexa treatment, but without weight gains seen with Zyprexa. . .

Zyprexa, whose U.S. patent lapses in 2011, is Lilly's best selling-product but its U.S. sales have been badly hurt by the drug's tendency to cause weight gains that can lead to diabetes. The new drug, if it eventually is approved, could help Lilly remain a major player in the field.